106 patients have now been enrolled in the prospective, nonrandomized trial in multiple centers in Europe and New Zealand.
Intended for use in conjunction with a commercially available drug-coated balloon, the Temporary Spur Stent features a self-expanding nitinol scaffold with radially expanding spikes designed to penetrate the diseased vessel wall and enhance drug delivery, without leaving anything behind.
Andrew Holden, MD, director of Interventional Radiology at Auckland City Hospital and Professor of Radiology at the University of Auckland, is also one of the Principal Investigators for the Temporary Spur Stent System trial.
Reflow Medical is in the design and development of innovative and effective technologies for cardiovascular disease.
The Reflow product portfolio includes products used to treat cardiovascular disease in the peripheral vasculature as well as the coronary arteries.
First Patient Dosed in Phase 2 Clinical Study Evaluating HTD1801 in Type 2 Diabetes Mellitus
ARX788 Included in the I-SPY 2.2 Phase 2 Adaptive Clinical Trial for Breast Cancer
Roche first quarter sales up by 10% on strong demand for rapid COVID-19 antigen tests
STENTiT concludes EUR1.8m as part of seed investment round
Dr. Reddy's Laboratories Launches Posaconazole Delayed-Release Tablets in the US Market
Former ViaCyte CEO Paul Laikind Joins Stemson Therapeutics Board of Directors